Tegaserod Novartis

IDrugs

Volumn 5, Issue 2, 2002, Pages 171-179

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (DIETHYLAMINO)ETHYL ESTER; 5 METHOXYTRYPTAMINE; ALOSETRON; CILANSETRON; CISAPRIDE; DRUG METABOLITE; M 290; METOCLOPRAMIDE; MOSAPRIDE; MU OPIATE RECEPTOR AGONIST; OMEPRAZOLE; PENTAGASTRIN; PIBOSEROD; PLACEBO; PRUCALOPRIDE; R 076186; RENZAPRIDE; SB 203816; SEROTONIN; SEROTONIN 4 AGONIST; SULAMSEROD; TEGASEROD; TICALOPRIDE; UK 321130; UNCLASSIFIED DRUG; ZACOPRIDE;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; LOW DRUG DOSE; META ANALYSIS; NAUSEA; NONHUMAN; PAIN; QUALITY OF LIFE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0141508823     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. 4 receptors in the isolated guinea pig ileum. Buchheit K-H, Gamse R, Pfannkuche H-J Naunyn Schmiedeberg's Arch Pharmacol 1992 345 4 387-393
2. 4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of antagonists. Buchheit K-H, Gamse R, Giger R, Hoyer D, Klein F, Kloppner E, Pfannkuche HJ, Mattes H J Med Chem 1995 38 13 2331-2338
3. 237084 Preclinical and clinical effects of SDZ HTF 919, a new prokinetic drug, on colonic transit. Appel S, Buchheit K-H, Kumle A, Thebault JJ Naunyn Schmiedeberg's Arch Pharmacol 1996 353 4 Suppl R143
4. 4 receptor. Kuemmerle JF, Murthy KS, Grider JR, Makhlouf GM Gastroenterology 1998 110 4 Suppl A1091
5. 4 agonist, stimulates canine colonic motility and transit in vivo. Nguyen A, Camilleri M, Kost LJ, Metzger A, Hanson RB, Sarr MG, Fett SL, Zinsmeister AR Gastroenterology 1996 110 4 Suppl A724
6. 4 receptor agonist, SDZ-HTF-919 in humans. Appel S, Lemarechal MO, Kumle A, Hubert M, Legangneux E Clin Pharmacol Ther 1997 61 2 158
7. 246051 SDZ HTF 919 stimulates canine colonic motility and transit in vivo. Nguyen A, Camilleri M, Kost LJ, Metzger A, Sarr MG, Hanson RB, Fett SL, Zinsmeister AR J Pharmacol Exp Ther 1997 280 3 1270-1276
8. 253214 First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. Appel S, Kumle A, Hubert M, Duvauchelle T J Clin Pharmacol 1997 37 3 229-237
9. 4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. Buchheit KH, Gamse R, Giger R, Hoyer D, Klein F, Kloppner E, Pfannkuche HJ, Mattes H J Med Chem 1995 38 13 2326-2330
10. 4 receptor agonist, in a model of slow colonic transit. Appel S, Kumle A, Meier R Clin Pharmacol Ther 1997 62 5 546-555
11. 286804 Annual Report 1997 - Novartis AG. Novartis AG Company Annual Report 1997 Dec 31
12. 4 receptors. Hoyer D, Fehlmann D, Langenegger D, Kummer J, Giger R, Mattes H, Probst A, Buchheit K-H, Pfannkuche HJ Naunyn Schmiedeberg's Arch Pharmacol 1998 357 4 Suppl R29
13. 4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: Effects on gastrointestinal motility and impaired gastric emptying. Fioramonti J, Million M, Bueno L Gastroenterology 1998 114 4 Pt 2 A752
14. 310016 5-Hydroxytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Grider JR, Foxx-Orenstein AE, Jin JG Gastroenterology 1998 115 2 370-380
15. 311514 Promise for millions of patients with Irritable Bowel Syndrome: Preliminary results of new clinical research at Novartis. Novartis AG Press Release 1998 September 06
16. 338831 Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. Drici MD, Ebert SN, Wang WX, Rodrigue I, Liu XK, Whitfield BH, Woolsey RL J Cardiovasc Pharmacol 1999 34 1 82-88 Lack of effects of tegaserod on the QT interval.
17. 342937 Novartis R&D Investor Seminar, New York. Company World Wide Web 1999 Sep 21
18. 344287 Drug development pipeline: Prucalopride. Janssen Pharmaceutica NV Company Comunication 1999 October 21
19. 344545 Novartis' Zelmac (tegaserod) shows promising role in treating irritable bowel syndrome (IBS). Novartis AG Press Release 1999 October 22 Press release summarizing phase III results.
20. 350878 Zelmac (tegaserod) achieves fast, effective relief of irritable bowel syndrome in large international study. Novartis AG Press Release 1999 November 13 Press release summarizing phase III results.
21. 3 receptors. Jin JG, Foxx-Orenstein AE, Grider JR J Pharmacol Exp Ther 1999 288 1 93-97 Effects on guinea pig colonic motility.
22. 4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Prins NH, Van Haselen JF, Lefebvre RA, Briejer MR, Akkermans LM, Schuurkes JA Br J Pharmacol 1999 127 6 1431-1437 Comparative potency of agents such as tegaserod, cisapride and prucalopride.
23. 361833 Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). Zhou H, Khalilieh S, Lau H, Guerret M, Osborne S, Alladina L, Laurent AL, McLeod JF J Clin Pharmacol 1999 39 9 911-919 Clinical pharmacokinetics of tegaserod.
24. 4 receptor agonist, following oral and intravenous administration. Appel-Dingemanse S, Lemarechal MO, Kumle A, Hubert M, Legangneux E Br J Clin Pharmacol 1999 47 5 483-491 Clinical pharmacokinetics of tegaserod.
25. 362853 Zelmac (tegaserod) granted priority review by FDA for the treatment of irritable bowel syndrome. Novartis AG Press Release 1999 Sep 21
26. 4 receptor partial agonist tegaserod (HTF 919). Appel-Dingemanse S, Horowitz A, Campestrini J, Osborne S, McLeod J Eur Gastroenterol Week 1999 November 17 The lack of absorption problems in older patients.
27. 4 receptor partial agonist tegaserod (HTF 919) improves abdominal bloating and altered stool consistency in IBS. Krumholz S, Tanghe J, Schmitt C, Heggland J, Shi Y, Ruegg PC Eur Gastroenterol Week 1999 November 17 Long-term data from 12-month open study.
28. 364540 Short- and long-term safety and tolerability of tegaserod (HTF 919) in patients with irritable bowel syndrome (IBS). Whorwell P, Muller-Lissner S, Langaker KJ, Wald A, Pruitt R, Ruegg P Eur Gastroenterol Week 1999 November 16 Phase III efficacy data.
29. 364458 Effects of tegaserod (HTF 919) on gastrointestinal motility and transit in awake rats. Huge A, Zittel TT, Kreis HE, Becker HD, Jehle EC Gastroenterology 2000 118 4 Suppl 2 Abs 2100 Effects on gastrointestinal motility in rats.
30. 372223 Similar pharmacokinetics of tegaserod (HTF 919) in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Appel-Dingemanse S, Rawls J, Heggland J, Campestrini J, Sechaud R Gastroenterology 2000 118 4 Suppl 2 (Pt 2) Abs 5340 Comparative pharmacokinetics in constipation-dependent and diarrhea-dependent IBS patients.
31. 372467 Effect of gastric pH on plasma concentrations of tegaserod (HTF 919) and its major metabolite in healthy subjects. Zhou H, Khaliliens S, Campestrini J, Appel-Dingemanse S, Lachman L, McLeod JF Gastroenterology 2000 118 4 Suppl 2 Abs 5538 The metabolism of tegaserod is increased at low pH.
32. 372970 Two clinical trials of irritable bowel syndrome with tegaserod (HTF 919) validate global relief measure. Lefkowitz M, Ruegg P, Dunger-Baldauf C, Shi Y J Gastroenterol Hepatol 2000 15 March 10-14 Abs 442 Subjective analysis of two phase III trials.
33. 372973 Tegaserod pharmacokinetics (PK) are similar in different types of irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD). Appel-Dingemanse S, Campestrini J, Rawls J, Sechaud R J Gastroenterol Hepatol 2000 15 March 10-14 Abs 443 Comparative pharmacokinetics in constipation-dependent and diarrhea-dependent IBS patients with GERD patients.
34. 4 receptor partial agonist tegaserod (HTF 919) accelerates upper and lower gastrointestinal (GI) transit. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Maecke H, Beglinger C J Gastroenterol Hepatol 2000 15 March 10-14 Abs 441 Comparative efficacy of intravenous and oral dosing in man.
35. 388367 The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Kahrilas PJ, Quigley EMM, Castell DO, Spechler SJ Aliment Pharmacol Ther 2000 14 11 1503-1509 The effects of tegaserod in GERD patients.
36. 4 receptor agonists stimulate small intestinal transit but do not have direct visceral antinociceptive effects in the rat. Hicks GA, Clayton NM, Gaskin PJ, Kirkup AJ, Su X, Joshi S, Friedrich A, Connor HE, Cox B, Grundy D, Gerbhart GF Gastroenterology 2001 120 5 (Suppl 1) Abs 27 In vivo comparison with prucalopride.
37. 408819 Tegaserod provides relief of symptoms in female patients with irritable bowel syndrome (IBS) suffering from abdominal pain and discomfort, bloating and constipation. Leftkowitz M, Ligozio G, Glebas K, Heggland JE, Ruegg PC Gastroenterology 2001 120 5 (Suppl 1) Abs 104 Results of a 12-week phase III study in 1519 patients.
38. 4 receptor partial agonist, devoid of significant electrocardiographic effects. Rueegg P, Baldauf CD, Dingemanse SA, Lefkowitz M, Morganroth J Gastroenterology 2001 120 5 Suppl 1 Abs 3257
39. 410922 Early effect of tegaserod predicts continued efficacy in treatment of constipation predominant irritable bowel syndrome. Muller-Lissner S, Lefkowitz M, Shi Y, Nault B, Heggland J, Glebas K, Ruegg PC Gastroenterology 120 5 (Suppl 1) Abs 3259 Analysis of phase III studies to assess onset of therapeutic effects.
40. 416098 Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G Gastroenterology 2000 10 5 463-468 The stimulation of human orocecal transport by tegaserod.
41. 416879 Novartis launches irritable bowel syndrome treatment Zelmac in first market, Mexico. Novartis AG Press Release 2001 July 25
42. 419544 Novartis reports sustained growth in first half of 2001. Novartis AG Press Release 2001 Aug 16
43. 422783 Global Healthcare Bulletin. Merrill Lynch Capital Markets 2001 June 19
44. 422835 Rome I versus Rome II: Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS). Nault B, Sam S, Heggland JE, Gohari S, Ligozio G, D'Agay L Gastroenterology 2001 120 Abs 1472 Assessment of the impact of using Rome 2 criteria on the outcome of tegaserod phase III trials.
45. 422838 Serotonergic modulation and irritable bowel syndrome. Borman R Exp Opin Emerg Drugs 2001 6 1 57-68
46. 428551 Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Muller Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Ruegg P Aliment Pharmacol Ther 2001 15 10 1655-1666
47. 441515 Drug development pipeline: Tegaserod. Novartis Pharma AG Company Communication 2001 October 12
48. 441519 Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Degen L, Matzinger D, Appel-Dingemanse S, Appel-Dingemanse S, Lunchinger S, Bertold R, Maecke H, Beglinger C Aliment Pharmacol Ther 2001 15 11 1745-1751
49. 441523 Zelmac™ (tegaserod) Advisory Committee Briefing Document. Novartis Pharmaceuticals Corp Internet Site 2000 May 24